DELAWARE, OH, United States
DELAWARE, OH, United States
SEARCH FILTERS
Time filter
Source Type

Joyner J.C.,Ohio State University | Reichfield J.,Ohio State University | Cowan J.A.,Ohio State University | Cowan J.A.,Metallopharm, Llc
Journal of the American Chemical Society | Year: 2011

A library of complexes that included iron, cobalt, nickel, and copper chelates of cyclam, cyclen, DOTA, DTPA, EDTA, tripeptide GGH, tetrapeptide KGHK, NTA, and TACN was evaluated for DNA nuclease activity, ascorbate consumption, superoxide and hydroxyl radical generation, and reduction potential under physiologically relevant conditions. Plasmid DNA cleavage rates demonstrated by combinations of each complex and biological co-reactants were quantified by gel electrophoresis, yielding second-order rate constants for DNA supercoiled to DNA nicked conversion up to 2.5 × 10 6 M -1 min -1, and for DNA nicked to DNA linear up to 7 × 10 5 M -1 min -1. Relative rates of radical generation and characterization of radical species were determined by reaction with the fluorescent radical probes TEMPO-9-AC and rhodamine B. Ascorbate turnover rate constants ranging from 3 × 10 -4 to 0.13 min -1 were determined, although many complexes demonstrated no measurable activity. Inhibition and Freifelder-Trumbo analysis of DNA cleavage supported concerted cleavage of dsDNA by a metal-associated reactive oxygen species (ROS) in the case of Cu 2+(aq), Cu-KGHK, Co-KGHK, and Cu-NTA and stepwise cleavage for Fe 2+(aq), Cu-cyclam, Cu-cyclen, Co-cyclen, Cu-EDTA, Ni-EDTA, Co-EDTA, Cu-GGH, and Co-NTA. Reduction potentials varied over the range from -362 to +1111 mV versus NHE, and complexes demonstrated optimal catalytic activity in the range of the physiological redox co-reactants ascorbate and peroxide (-66 to +380 mV). © 2011 American Chemical Society.


Joyner J.C.,Ohio State University | Cowan J.A.,Ohio State University | Cowan J.A.,Metallopharm, Llc
Journal of the American Chemical Society | Year: 2011

A series of compounds that target reactive metal chelates to the HIV-1 Rev response element (RRE) mRNA have been synthesized. Dissociation constants and chemical reactivity toward HIV RRE RNA have been determined and evaluated in terms of reduction potential, coordination unsaturation, and overall charge associated with the metal-chelate-Rev complex. Ethylenediaminetetraacetic acid (EDTA), nitrilotriacetic acid (NTA), diethylenetriaminepentaacetic acid (DTPA), and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) were linked to a lysine side chain of a Rev-derived peptide by either EDC/NHS or isothiocyanate coupling. The resulting chelate-Rev (EDTA-Rev, DTPA-Rev, NTA-Rev, and DOTA-Rev) conjugates were used to form coordination complexes with Fe 2+, Co2+, Ni2+, and Cu2+ such that the arginine-rich Rev peptide could mediate localization of the metal chelates to the Rev peptide's high-affinity mRNA binding partner, RRE stem loop IIB. Metal complexes of the extended peptides GGH-Rev and KGHK-Rev, which also contain N-terminal peptidic chelators (ATCUN motifs), were studied for comparison. A fluorescence titration assay revealed high-affinity RRE RNA binding by all 22 metal-chelate-Rev species, with KD values ranging from ∼0.2 to 16 nM, indicating little to no loss of RNA affinity due to the coupling of the metal chelates to the Rev peptide. Dissociation constants for binding at a previously unobserved low-affinity site are also reported. Rates of RNA modification by each metal-chelate-Rev species were determined and varied from ∼0.28 to 4.9 nM/min but were optimal for Cu2+-NTA-Rev. Metal-chelate reduction potentials were determined and varied from -228 to +1111 mV vs NHE under similar solution conditions, allowing direct comparison of reactivity with redox thermodynamics. Optimal activity was observed when the reduction potential for the metal center was poised between those of the two principal co-reagents for metal-promoted formation of reactive oxygen species: E°ascorbate/ascorbyl-radical = -66 mV and E°H 2O2/hydroxyl-radical = 380 mV. Given the variety of oxidative activities of these metal complexes and their high-affinity binding to the targeted RRE mRNA following coupling to the Rev peptide, this class of metal-chelate-Rev derivatives constitutes a promising step toward development of multiple-turnover reagents for selective eradication of HIV-1 RRE mRNA. © 2011 American Chemical Society.


It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a ligand moiety) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a metallodrug or metallotherapeutic. The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.


It is an object of the present invention to provide improved pharmacological properties to molecules which bind to a target with low affinity (hereinafter referred to as a ligand moiety) through linkage of such molecules to a metal binding moiety, thereby generating a combination molecule commonly referred to as a metallodrug or metallotherapeutic. The metal binding domain of metallodrugs typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, resulting in modification of proteins and nucleic acids that are in close proximity due to binding of the ligand moiety to its target.


It is an object of the present invention to provide antimicrobial metallodrugs comprising an antimicrobial peptide (AMP) and/or an antibiotic covalently bound to a metal binding moiety. These metallodrugs combine a metal binding domain which typically catalyzes oxido-reductase chemistry or acts as a Lewis-Acid catalyst, with a member of a diverse class of antimicrobial agents currently validated in preclinical and clinical settings for the treatment of a broad spectrum of pathogenic organisms.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 224.97K | Year: 2016

DESCRIPTION provided by applicant In the United States chronic wounds represent a major public health burden on patients as well as the health care economy Estimates put the number of chronic wounds cases at over million with a cost burden of over $ billion It is estimated that at least two thirds of all chronic wounds are infected with biofilm forming bacteria Recent studies also found that surgical site infections SSIs were the most common healthcare associated infection HAI accounting for of all HAIs among hospitalized patients While advances have been made in infection control practices SSIs remain a substantial cause of morbidity prolonged hospitalization and death and rising economic burdens on the human population Therefore there is a critical need for rapid and accurate diagnosis and treatment of the infection in acute or chronic wounds to aid in the proper healing of the wounds themselves Rapid point of care PoC pathogen identification ID and antimicrobial susceptibility testing AST decrease indiscriminate antibiotic use and accelerate pathogen directed application to avoid inappropriate prescription of antibiotics MetalloPharm is developing an innovative device that will meet these requirements for a useful PoC product The specific goal is to develop rapid low cost simple to use PoC pathogen ID and AST products that provide clinicians with actionable results to aid in wound infection diagnosis and treatment within hour where the availability of real time data for the practicing physician will make significant differences in th choice and timing of antibiotic treatment The format is a simple step test involving direct mixing of sample and up to a h waiting period to yield a yes no color change Yes No infection based on a CFU threshold that is read by the naked eye There is no requirement for training or special instrumentation and no need for colony isolation and culture enrichment Expected Outcome To provide clinicians with actionable results for wound sample diagnosis with a rapid PoC pathogen ID within h an accompanying AST readout These studies will result in a novel and practical tool for the detection of bacteria in wound samples especiall because the AST can be performed concurrently The novelty and high clinical impact of this potential PoC diagnostic will create a paradigm shift in the clinical treatment of wound infection and healing PUBLIC HEALTH RELEVANCE Our primary goal is to develop rapid low cost simple to use PoC pathogen ID and AST products that provide clinicians with actionable results to aid in wound infection diagnosis and treatment within hour where the availability of real time data for the practicing physician will make significant differences in the choice and timing of antibiotic treatment The diagnostic is a simple step test involving direct mixing of sample and a hr waiting period to yield a yes no color change for Yes No infection that is read by the naked eye There is no requirement for training or special instrumentation and no need for colony isolation and culture enrichment


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 224.87K | Year: 2014

Multidrug-resistant tuberculosis (MDR-TB) is an increasing challenge for the treatment of TB. Currently existing drugs for the treatment of MDR TB are only moderately potent, show restrictions with absorption or oral bioavailability, and have toxicity profiles that make patient management difficult. Current international guidelines for the treatment of MDR-TB include at least one second-line agent administered by injection. There are two important classes of injectable drugs: the aminoglycosides (amikacin and kanamycin) and the polypeptide capreomycin. Capreomycin is specifically recommended for use in cases of known or suspected resistance to the aminoglycosides. Capreomycin also seems to have activity against non-replicating persister bacilli, unlike aminoglycosides. The drug is painful to receive by injection and is associated with severe systemic side effects, including nephrotoxicity and ototoxicity. The goal of this project is to develop novel formulations or modifications of capreomycin that can be orally administered, maintain efficacy, possibly decrease adverse events (nephrotoxicity and ototoxicity), and used as part of a drug regimen for the treatment of MDR-TB. PUBLIC HEALTH RELEVANCE


Grant
Agency: NSF | Branch: Standard Grant | Program: | Phase: | Award Amount: 150.00K | Year: 2014

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a simple general test strip that can be broadly used for the detection and characterization of bacteria such as pathogens and drug-resistant organisms. The project is expected to result in a prototype low-cost device for rapid and specific characterization of bacteria. The product will take the form similar to that of a home pregnancy test and will be ideal for immediate point-of-care diagnoses. There is no such general product currently on the market and commercial potential is deemed high. The proposed diagnostic platform will be versatile and broadly applicable for different applications.


The proposed project is to deliver a low-cost, simple, handheld product that gives a rapid and accurate visible colorimetric indication (Yes or NO answer similar to a pregnancy home test strip) of bacteria relevant to disease, biowarfare concerns, environmental contamination, and the food chain. There is a need for a rapid, simple and inexpensive point-of-care test, especially in hospital ICU?s where there is a high risk and frequency of getting infection from sick patients who have compromised immune systems. The detection platform is versatile and applicable to a large array of microbial infections, and has multiple applications in clinical and non-clinical setting. It is intended to transform the way pathogens are detected in the professional and consumer markets. The proposal seeks to develop the design principles and fashioning of practical devices to achieve a rapid diagnostic kit for identification of bacteria using human samples.


Grant
Agency: National Science Foundation | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 150.00K | Year: 2014

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a simple general test strip that can be broadly used for the detection and characterization of bacteria such as pathogens and drug-resistant organisms. The project is expected to result in a prototype low-cost device for rapid and specific characterization of bacteria. The product will take the form similar to that of a home pregnancy test and will be ideal for immediate point-of-care diagnoses. There is no such general product currently on the market and commercial potential is deemed high. The proposed diagnostic platform will be versatile and broadly applicable for different applications. The proposed project is to deliver a low-cost, simple, handheld product that gives a rapid and accurate visible colorimetric indication (Yes or NO answer similar to a pregnancy home test strip) of bacteria relevant to disease, biowarfare concerns, environmental contamination, and the food chain. There is a need for a rapid, simple and inexpensive point-of-care test, especially in hospital ICU?s where there is a high risk and frequency of getting infection from sick patients who have compromised immune systems. The detection platform is versatile and applicable to a large array of microbial infections, and has multiple applications in clinical and non-clinical setting. It is intended to transform the way pathogens are detected in the professional and consumer markets. The proposal seeks to develop the design principles and fashioning of practical devices to achieve a rapid diagnostic kit for identification of bacteria using human samples.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 2.00M | Year: 2011

DESCRIPTION (provided by applicant): HCV is responsible for 60% of the cases of chronic hepatitis and 50% of cases of cirrhosis, end- stage liver disease, and liver cancer. An effective vaccine has proved elusive and the preferred therapy with pegylated interferon is effective in less than 50% of patients with genotype 1 and 75% of patients with genotypes 2 or 3. Clearly, new treatment alternatives are needed. Interest in HCV IRES RNA as a drug target is reflected by the increasing number of small and largepharma companies pursuing that goal. MetalloPharm has created a novel platform technology (metallodrugs) that has the potential to irreversibly destroy the HCV IRES RNA. The specific aims are directed toward selection of a lead and back-up drug candidatefor IND-enabling pre- clinical testing following validation of cellular mode of action against IRES RNA and uptake mechanisms; assessment of PK, toxicity and efficacy data; and exploration of methods to improve serum half life. PUBLIC HEALTH RELEVANCE: Millions of people worldwide are infected with HCV, including a significant portion of the US population. HCV is responsible for 60% of the cases of chronic hepatitis and 50% of cases of cirrhosis, end-stage liver disease, and liver cancer. An effective vaccine has proved elusive and current therapy is effective in less than 50% of patients. Clearly, new treatment alternatives are needed. MetalloPharm has created a novel class of therapeutics (metallodrugs) that function by destroying a key molecule inthe viral life cycle with the potential to halt the progression of, or completely eliminate the virus.

Loading Metallopharm, Llc collaborators
Loading Metallopharm, Llc collaborators